Our top pick for
Inhibrx Inc is a biotechnology business based in the US. Inhibrx shares (INBX) are listed on the NASDAQ and all prices are listed in US Dollars. Inhibrx employs 84 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$38.14|
|52-week range||$14.27 - $50.97|
|50-day moving average||$33.47|
|200-day moving average||$26.15|
|Wall St. target price||$47.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.23|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-3.95%|
|1 month (2021-09-24)||3.73%|
|3 months (2021-07-23)||31.52%|
|6 months (2021-04-23)||100.95%|
|1 year (2020-10-23)||99.27%|
|2 years (2019-10-20)||N/A|
|3 years (2018-10-20)||N/A|
|5 years (2016-10-20)||N/A|
|Revenue TTM||$10.5 million|
|Gross profit TTM||$-60,607,000|
|Return on assets TTM||-54.4%|
|Return on equity TTM||-567.79%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
There are currently 856,535 Inhibrx shares held short by investors – that's known as Inhibrx's "short interest". This figure is 17.6% up from 728,424 last month.
There are a few different ways that this level of interest in shorting Inhibrx shares can be evaluated.
Inhibrx's "short interest ratio" (SIR) is the quantity of Inhibrx shares currently shorted divided by the average quantity of Inhibrx shares traded daily (recently around 147170.96219931). Inhibrx's SIR currently stands at 5.82. In other words for every 100,000 Inhibrx shares traded daily on the market, roughly 5820 shares are currently held short.
However Inhibrx's short interest can also be evaluated against the total number of Inhibrx shares, or, against the total number of tradable Inhibrx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inhibrx's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Inhibrx shares in existence, roughly 20 shares are currently held short) or 0.0491% of the tradable shares (for every 100,000 tradable Inhibrx shares, roughly 49 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Inhibrx.
Find out more about how you can short Inhibrx stock.
We're not expecting Inhibrx to pay a dividend over the next 12 months.
Inhibrx, Inc. , a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.